Singapore markets close in 4 hours 16 minutes

Straits Times Index
3,283.24
-9.89(-0.30%)
Nikkei
37,695.84
-764.24(-1.99%)
Hang Seng
17,295.93
+94.66(+0.55%)
FTSE 100
8,040.38
-4.43(-0.06%)
Bitcoin USD
64,278.55
-2,460.73(-3.69%)
CMC Crypto 200
1,386.12
-37.98(-2.67%)

Merrimack Pharmaceuticals, Inc. (MACK)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

14.71

-0.02

(-0.14%)

At close: 04:00PM EDT

14.71

0.00

(0.00%)

After hours:

04:01PM EDT

Trade prices are not sourced from all markets

Press releases

Business Wire
Merrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
Business Wire
Merrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Business Wire
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
CAMBRIDGE, Mass., February 13, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC).